by Dennis Crouch
Amgen v. Sanofi and Regeneron (Fed. Cir. 2021)
The decision here provides another anti-functional-limitation decision — this time rendering Amgen’s monoclonal antibody claims invalid. Although enablement decisions traditionally differed grea Read More>>
Categories Patent
